Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.47 |
| ▸ | ACACA | Q13085 | 4/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31424441 | 0.85 | PARP10 (0.51) | PARP10PARP15 | |
| SCHEMBL9931973 | 0.85 | PARP10 (0.51) | PARP10PARP15 | |
| SCHEMBL19951551 | 0.79 | PARP15 (0.46) | ACACBPARP10PARP15 | |
| SCHEMBL29993061 | 0.79 | PARP15 (0.46) | ACACBPARP10PARP15 | |
| SCHEMBL17050486 | 0.78 | ACACB (0.54) | ACACBACACAPARP10PARP15CYP2C9 | |
| SCHEMBL19874193 | 0.76 | PARP10 (0.51) | PARP10PARP15TRPV4 | |
| SCHEMBL17050473 | 0.76 | ACACB (0.57) | ACACBACACAPARP10PARP15CYP2C9 | |
| SCHEMBL16758052 | 0.76 | SLC6A2 (0.58) | PARP10PARP15 | |
| SCHEMBL13262900 | 0.75 | PARP10 (0.43) | PARP10PARP15FFAR1PPARD | |
| Hydrochloric Acid SCHEMBL15539090 | 0.75 | SLC6A2 (0.57) | PARP10PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | ACACB 2/4885ACACA 10/4885PARP10 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.